Table 2.
Non-small cell lung cancer (NSCLC) cohorts explored in this study: platinum-based chemotherapy (NSCLC-PLAT) and trimodality therapy (NSCLC-TRI).
| NSCLC-PLAT | NSCLC-TRI | |
|---|---|---|
| N | 97 | 90 |
| Pathologic Response | ||
| Major pathologic response (MPR) | N/A | 37 |
| non-MPR | N/A | 53 |
| Imaging Response | ||
| Response/Stable Disease | 50 | 36 |
| Progressive Disease | 47 | 54 |
| Survival | ||
| Event type | Progression | Recurrence |
| Event observed, N [median time-to-event, months] | 75 [1.0] | 37 [17.6] |
| Censored, N [median time-to-last-followup, months] | 17 [36.0] | 53 [40.0] |
| Unavailable | 5 | 0 |
| Histology | ||
| Adenocarcinoma, N | 70 | 65 |
| Squamous Cell Carcinoma/Other, N | 27 | 25 |
| Stage | ||
| I, N | 4 | 0 |
| II, N | 1 | 0 |
| III, N | 20 | 90 [84 IIIA, 6 IIIB] |
| IV, N | 69 | 0 |
| N/A, N | 3 | 0 |
| Sex | ||
| Male, N | 51 | 49 |
| Female, N | 43 | 41 |
| N/A, N | 3 | 0 |
| Smoking history | ||
| Past smoker, N | 79 | -- |
| Non-smoker, M | 15 | -- |
| N/A, N | 3 | 90 |
| ECOG Performance Status | ||
| 0, N | -- | 17 |
| 1, N | -- | 66 |
| N/A, N | 97 | 7 |
| Age, years | 61.0 ± 13.0 | 63.2 ± 10.6 |
| Longest diameter, mm | 46.3 ± 31.7 | 52.2 ± 30.2 |
| Cohort | ||
| Training | 53 | 44 |
| Testing | 44 | 46 |